PET imaging of demyelination and remyelination in the cuprizone mouse model for multiple sclerosis: A comparison between [11C]CIC and [11C]MeDAS

NeuroImage

Volumn 87, Issue , 2014, Pages 395-402

  de Paula Faria, Daniele ^a,b   De Vries, Erik F J ^a   Sijbesma, Jurgen W A ^a   Dierckx, Rudi A J O ^a   Buchpiguel, Carlos A ^b   Copray, Sjef ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cuprizone model; Demyelination; Multiple Sclerosis; Myelin; PET imaging; Remyelination

Indexed keywords

CARBON CIC C 11; CARBON MEDAS C 11; CUPRIZONE; RADIOLIGAND; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CONTROLLED STUDY; CORPUS CALLOSUM; DEMYELINATION; DIET; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG UPTAKE; EX VIVO BIODISTRIBUTION; EX VIVO STUDY; HISTOCHEMISTRY; INTERMETHOD COMPARISON; ISOTOPE LABELING; MALE; MOUSE; MULTIPLE SCLEROSIS; MYELIN SHEATH; MYELINATION; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REMYELINIZATION;

CUPRIZONE MODEL; DEMYELINATION; MAGNETIC RESONANCE IMAGING; MRI; MS; MULTIPLE SCLEROSIS; MYELIN; PET; PET IMAGING; POSITRON EMISSION TOMOGRAPHY; REMYELINATION; STANDARDIZED UPTAKE VALUE; SUV;

ANIMALS; CARBON RADIOISOTOPES; CHELATING AGENTS; CUPRIZONE; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84891942543     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2013.10.057     Document Type: Article

References (25)

1. Briard E., Orain D., Beerli C., Billich A., Streiff M., Bigaud M., Auberson Y.P. BZM055, an iodinated radiotracer candidate for PET and SPECT imaging of myelin and FTY720 brain distribution. ChemMedChem 2011, 6:667-677.
2. Calderini G., Bonetti A.C., Battistella A., Crews F.T., Toffano G. Biochemical changes of rat brain membranes with age. Neurochem. Res. 1983, 8(4):483-492.
3. Elsinga P.H. Radiopharmaceutical chemistry for positron emission tomography. Methods 2002, 27:208-217.
4. Fillip M., Rocca M.S. MR imaging of multiple sclerosis. Radiology 2011, 259(3):659-681.
5. Frullano L., Wang C., Miller R.H., Wang Y. A myelin-specific contrast agent for magnetic resonance imaging of myelination. J. Am. Chem. Soc. 2011, 133:1611-1613.
6. Herrero P., Markham J., Bergmann S.R. Quantitation of myocardial blood flow with 215O and positron emission tomography: assessment and error analysis of a mathematical approach. J. Comput. Assist. Tomogr. 1989, 13(5):862-873.
7. Inglese M., Bester M. Diffusion imaging in multiple sclerosis: research and clinical implications. NMR Biomed. 2010, 23:865-872.
8. Kipp M., Clarner T., Dang J., Copray S., Beyer C. The cuprizone animal model: new insights into an old story. Acta Neuropathol. 2009, 118:723-736.
9. Koeppe R.A. PET Pharmacokinetic Course Manual 2007, (Chapter 11, Kobe, Japan). R.P. Maguire, K.L. Leenders (Eds.).
10. Li Z., Conti P.S. Radiopharmaceutical chemistry for positron emission tomography. Adv. Drug Deliv. Rev. 2010, 62:1031-1051.
11. Matsushima G.K., Morel P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol. 2001, 11:107-116.
12. Muzic R.F., Chen C.-H., Nelson A.D. A method to correct for scatter, spillover, and partial volume effects in region of interest analysis in PET. IEEE Trans. Med. Imaging 1998, 17:202-213.
13. Ohama E., Horikawa Y., Shimizu T., Morita T., Nemoto K., Tanaka H., Ikuta F. Demyelination and remyelination in spinal cord lesions of human lymphotropic virus type I-associated myelopathy. Acta Neuropathol. 1990, 81:78-83.
14. Patrikios P., Stadelmann C., Kutzelnigg A., Rauschka H., Schmidbauer M., Laursen H., Sorensen P.S., Brück W., Lucchinetti C., Lassmann H. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006, 129:3165-3172.
15. Shrager P. Ionic channels and signal conduction in single remeylination frog nerve fibers. J. Physiol. 1988, 404:695-712.
16. Stankoff B., Wang Y., Bottlaender M., Aigrot M.S., Dolle F., Wu C., Feinstein D., Huang G.F., Semah F., Mathis C.A., Klunk W., Gould R.M., Lubetzki C., Zalc B. Imaging of CNS myelin by positron-emission tomography. PNAS 2006, 103(24):9304-9309.
17. Steelman A.J., Thompson J.P., Li J. Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication. Neurosci. Res. 2012, 72(1):32-42.
18. Wang, Y., Wu, C.H., 2010. In vivo imaging of myelination. Patent number US2010/0221180 A1.
19. Wang Y., Wu C., Caprariello A.V., Somoza E., Zhu W., Wang C., Miller R.H. In vivo quantification of myelin changes in the vertebrate nervous system. J. Neurosci. 2009, 29(46):14663-14669.
20. Wang C., Wu C., Zhu J., Miller R.H., Wang Y. Design, synthesis, and evaluation of coumarin-based molecular probes for imaging of myelination. J. Med. Chem. 2011, 54(7):2331-2340.
21. WHO - World Health Organization Atlas Multiple Sclerosis Resources in the World 2008.
22. Wu C., Tian D., Feng Y., Polak P., Wei J., Sharp A., Stankoff B., Lubetzki C., Zalc B., Mufson E.J., Gould R.M., Feinstein D.L., Wang Y. A novel fluorescent probe that is brain permeable and selectively binds to myelin. J. Histochem. Cytochem. 2006, 54:997-1004.
23. Wu C., Wang C., Popescu D.C., Zhu W., Somoza E.A., Zhu J., Condie A.G., Flask C.A., Miller R.H., Macklin W., Wang Y. A novel PET marker for in vivo quantification of myelination. Bioorg. Med. Chem. 2010, 18:8592-8599.
24. Wu C., Zhu J., Baeslack J., Zaremba A., Hecker J., Kraso J., Matthews P.M., Miller R.H., Wang Y. Longitudinal PET imaging for monitoring myelin repair in the spinal cord. Ann. Neurol. 2013, (Epub ahead of print). 10.1002/ana.23965.
25. Zhang K., Sejnowski T.J. A universal scaling law between gray matter and white matter of cerebral cortex. PNAS 2000, 97:5621-5626.